Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Tessa Parkes, Rebecca Foster, Andrew McAuley, Deborah Steven, Catriona Matheson & Alex Baldacchino. (2023) Chronic pain, prescribed opioids and overdose risk: a qualitative exploration of the views of affected individuals and family members. Drugs: Education, Prevention and Policy 30:3, pages 229-240.
Read now
Read now
Ryan S D’Souza, Jennifer Eller & Chelsey Hoffmann. (2022) Pain and Analgesic Utilization in Medically Underserved Areas: Five-Year Prevalence Study from the Rochester Epidemiology Project. Journal of Pain Research 15, pages 1297-1304.
Read now
Read now
Articles from other publishers (11)
Eric L. Sevigny, Jared Greathouse & Danye N. Medhin. (2023) Health, safety, and socioeconomic impacts of cannabis liberalization laws: An evidence and gap map. Campbell Systematic Reviews 19:4.
Crossref
Crossref
Christian Gunadi & Yuyan Shi. (2023) Association between prescription drug monitoring programs use mandates and prescription stimulants received by Medicaid enrollees. Drug and Alcohol Review 42:7, pages 1658-1666.
Crossref
Crossref
Louisa Picco, Alison Ritter & Suzanne Nielsen. (2023) Prescription drug monitoring programs in Australia: A call for a comprehensive evaluation. Drug and Alcohol Review 42:4, pages 745-747.
Crossref
Crossref
Natasha L. Underwood, Heather Kane, Jessica Cance, Kyle Emery, Elvira Elek, William Zule, Cherie Rooks-Peck, Wesley Sargent & Jamie Mells. (2023) Achieving Reductions in Opioid Dispensing: A Qualitative Comparative Analysis of State-Level Efforts to Improve Prescribing. Journal of Public Health Management and Practice 29:2, pages 262-270.
Crossref
Crossref
Julia Dickson-Gomez, Sarah Krechel, Antoinette Spector, Margaret Weeks, Jessica Ohlrich, H. Danielle Green Montaque & Jianghong Li. (2022) The effects of opioid policy changes on transitions from prescription opioids to heroin, fentanyl and injection drug use: a qualitative analysis. Substance Abuse Treatment, Prevention, and Policy 17:1.
Crossref
Crossref
Lauren R. Gorfinkel, Deborah Hasin, Andrew J. Saxon, Melanie Wall, Silvia S. Martins, Magdalena Cerdá, Katherine Keyes, David S. Fink, Salomeh Keyhani, Charles C. Maynard & Mark Olfson. (2022) Trends in Prescriptions for Non-opioid Pain Medications Among U.S. Adults With Moderate or Severe Pain, 2014-2018. The Journal of Pain 23:7, pages 1187-1195.
Crossref
Crossref
Dimi Hoppe, Leila Karimi & Hanan Khalil. (2022) Mapping the research addressing prescription drug monitoring programs: A scoping review. Drug and Alcohol Review 41:4, pages 803-817.
Crossref
Crossref
Sumedha Gupta, Morhaf Al Achkar & Bradley Ray. (2021) Are prescription drug monitoring laws effective for all? Evidence from administrative data. Contemporary Economic Policy 40:1, pages 28-47.
Crossref
Crossref
Joe Schofield, Deborah Steven, Rebecca Foster, Catriona Matheson, Alexander Baldacchino, Andrew McAuley & Tessa Parkes. (2021) Quantifying prescribed high dose opioids in the community and risk of overdose. BMC Public Health 21:1.
Crossref
Crossref
Julia Dickson-Gomez, Erika Christenson, Margaret Weeks, Carol Galletly, Jennifer Wogen, Antoinette Spector, Madelyn McDonald & Jessica Ohlrich. (2021) Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin. Substance Abuse: Research and Treatment 15, pages 117822182199234.
Crossref
Crossref
William S. ShawCora RoelofsLaura Punnett. (2020) Work Environment Factors and Prevention of Opioid-Related Deaths. American Journal of Public Health 110:8, pages 1235-1241.
Crossref
Crossref